bioRxivCell BiologyPreprint
The loss of DNA polymerase epsilon accessory subunits POLE3-POLE4 leads to BRCA1-independent PARP inhibitor sensitivity
H. Mamar, R. Fajka-Boja, M. Morocz, E. P. Jurado, S. Zentout, A. Mihut, A. G. Kopasz, M. Merey, R. Smith, L. Haracska, S. Huet, G. Timinszky
Abstract
The clinical success of PARP1/2 inhibitors prompts the expansion of their applicability beyond homologous recombination deficiency. Here, we demonstrate that the loss of the accessory subunits of DNA polymerase epsilon, POLE3 and POLE4, sensitizes cells to PARP inhibitors. We show that the sensitivity of POLE4 knockouts is not due to a compromised response to DNA damage or homologous recombination deficiency. Instead, POLE4 deletion generates replication stress with the accumulation of single-stranded DNA gaps upon PARP inhibitor treatment. In POLE4 knockouts, replication stress leads to elevated DNA-PK signaling revealing a role of POLE4 in regulating DNA-PK activation. Moreover, POLE4 knockouts show synergistic sensitivity to the co-inhibition of ATR and PARP. Finally, POLE4 loss enhances the sensitivity of BRCA1-deficient cells to PARP inhibitors and counteracts acquired resistance consecutive to restoration of homologous recombination. Altogether, our findings establish POLE4 as a promising target to improve PARP inhibitor driven therapies and hamper acquired PARP inhibitor resistance.
- organism: human
- assay: DNA methylation
- assay: proteomics
- research focus: drug response / drug discovery
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of Nuclear DNA Ligase III Reverts PARP Inhibitor Resistance in BRCA1/53BP1 Double-deficient Cells by Exposing ssDNA Gaps
M. Paes Dias, V. Tripathi, … J. Jonkers·bioRxiv·Mar 24, 2021
- SETD1A-dependent EME1 transcription drives PARPi sensitivity in HR deficient tumour cells
Ellie Sweatman, Rachel Bayley, … Martin R. Higgs·British Journal of CancerPeer-reviewed·Feb 24, 2025
- Identification of regulators of poly-ADP-ribose polymerase (PARP) inhibitor response through complementary CRISPR knockout and activation screens
Kristen E. Clements, Emily M. Schleicher, … George‐Lucian Moldovan·Nature CommunicationsPeer-reviewed·Nov 30, 2020
- Synergistic effects of PARP inhibitors by Schlafen 11 and BRCA2-deficiency through accumulation of single-strand DNA gaps behind a fork
- Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells
K. E. Clements, T. Thakar, … G.-L. Moldovan·bioRxiv·Apr 3, 2018
- An inducible BRCA1 expression system with in vivo applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistance
Elsa Irving, Alaide Morcavallo, … Josep V. Forment·CancersPeer-reviewed·Jan 20, 2026